Shopping Cart

Your shopping cart is currently empty

Camonsertib

Name: Camonsertib
Brand: TargetMol
SKU: T62083
Price: 172 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T62083Cas No. 2417489-10-0

Alias RP-3500, ATR inhibitor 4

Camonsertib (RP-3500) is a novel, potent and selective ATR kinase inhibitor (ATRi) that exhibits potent antitumor effects with an IC50: 1.00 nM in biochemical assays.RP-3500 is 30-fold more selective for ATR than mTOR (IC50: 120 nM) and more than 2,000-fold more potent than ATM, DNA-PK and PI3Kα kinases. RP-3500 is 30 times more selective for ATR than mTOR (IC50: 120 nM), and 2,000 times more selective than ATM, DNA-PK and PI3Kα kinases.

Camonsertib

Copy Product Info

😃Good

Purity: 99.93%

Catalog No. T62083Alias RP-3500, ATR inhibitor 4Cas No. 2417489-10-0

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$172	In Stock	In Stock
5 mg	$438	In Stock	In Stock
10 mg	$637	In Stock	In Stock
25 mg	$993	In Stock	In Stock
50 mg	$1,320	-	In Stock
100 mg	$1,820	-	In Stock
200 mg	$2,450	-	In Stock
1 mL x 10 mM (in DMSO)	$396	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.93%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Camonsertib (RP-3500) is a novel, potent and selective ATR kinase inhibitor (ATRi) that exhibits potent antitumor effects with an IC50: 1.00 nM in biochemical assays.RP-3500 is 30-fold more selective for ATR than mTOR (IC50: 120 nM) and more than 2,000-fold more potent than ATM, DNA-PK and PI3Kα kinases. RP-3500 is 30 times more selective for ATR than mTOR (IC50: 120 nM), and 2,000 times more selective than ATM, DNA-PK and PI3Kα kinases.
Targets&IC50	ATR:1 nM, mTOR:120 nM
In vitro	METHODS: Characterization of the DNA damage response (DDR) to Camonsertib (RP-3500)-mediated ATR inhibition in LoVo and CW-2 human colon cancer cell lines treated with 1 μmol/L RP-3500 for varying durations up to 24 hours. RESULTS Camonsertib (RP-3500) inhibits CHK1 (Ser345) phosphorylation 1-3 hours after initiation of treatment. [2] METHODS: A biochemical assay for ATR/ATRIP inhibition was established using tagged human ATR and ATRIP purified from mammalian cells, with p53 (Ser15) as the phosphorylation substrate. RESULTS In a LoVo cell-based assay, Camonsertib (RP-3500) inhibited gemcitabine-stimulated phosphorylation of the ATR substrate pCHK1 (Ser345) with an IC50 of 0.33 nM. [2]
In vivo	METHODS: Patients received Camonsertib (RP-3500) at doses ranging from 5-200 mg once daily or 40 to 80 mg twice daily for 5 days/2 days off (5/2) or 3 days/4 days off ( 3/4), hematological parameters were assessed over a range of doses during treatment. RESULTS Early decrease in monocytes and reticulocytes on day 8 and further decrease in hemoglobin levels on day 15. [1] METHODS: Camonsertib (RP-3500) was used to treat LoVo tumor xenografts in mice, orally administered once a day at a dose of 3/7/15 mg/kg for 17 days, and the effect on LoVo tumor xenografts in mice was observed. RESULTS Camonsertib (RP-3500) treatment of LoVo tumor xenografts in mice produced dose-dependent tumor growth inhibition, with a minimum effective dose (MED) of 7 mg/kg. [2] METHODS: In the CW-2 colon xenograft model, Camonsertib (RP-3500) was administered at doses of 5 and 10 mg/kg to observe the effects on the growth of the mouse CW-2 colon xenograft model. RESULTS Treatment of xenograft mice with Camonsertib (RP-3500) produced statistically significant tumor growth inhibition. [2]
Synonyms	RP-3500, ATR inhibitor 4

Chemical Properties

Molecular Weight	410.47
Formula	C₂₁H₂₆N₆O₃
Cas No.	2417489-10-0
Smiles	C[C@@H]1COCCN1c1cc(c2cnn(-c3cc[nH]n3)c2n1)[C@@]1(O)C[C@@H]2CC[C@H](C1)O2

Storage & Solubility Information

Storage

store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45 mg/mL (109.63 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1.5 mg/mL (3.65 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4362 mL	12.1812 mL	24.3623 mL	121.8116 mL
5 mM	0.4872 mL	2.4362 mL	4.8725 mL	24.3623 mL
10 mM	0.2436 mL	1.2181 mL	2.4362 mL	12.1812 mL
20 mM	0.1218 mL	0.6091 mL	1.2181 mL	6.0906 mL
50 mM	0.0487 mL	0.2436 mL	0.4872 mL	2.4362 mL
100 mM	0.0244 mL	0.1218 mL	0.2436 mL	1.2181 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc